Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of TetraMen-T Vaccine in Adults, Toddlers, and Infants
NCT06165276Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jul 2006
- Primary completion
- Aug 2008
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, single-blind trial of meningococcal polysaccharide A, C, W and Y vaccine, tetanus toxoid conjugate in meningococcal disease (8 arms), sponsored by Sanofi. Primary endpoints: Presence of solicited injection site reactions at 7 days, Presence of any unsolicited systemic adverse events at 28 days and 2 more. Started Jul 2006; status: completed.
02
Drugs
meningococcal polysaccharide A, C, W and Y vaccine, tetanus toxoid conjugate
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT06165276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06165276.